## Molecular Mechanisms
This hypothesis posits a mechanistic link between **cellular senescence** and **complement-mediated synaptic damage** in Alzheimer's disease. The proposed pathway involves several interconnected cascades:
**1. SASP Induction and NF-κB Activation**
Senescent astrocytes and microglia exhibit chronic NF-κB activation, driving secretion of IL-1β, IL-6, TNF-α, and other SASP factors (PMID: 26437516). These cytokines create a pro-inflammatory milieu that can prime neighboring cells.
**2. Complement Upregulation via Glial NF-κB/STAT3**
SASP cytokines—particularly IL-1β and TNF-α—activate NF-κB signaling in microglia and astrocytes, transcriptionally upregulating complement components **C1Q (C1QA/C1QB/C1QC)** and **C3** (PMID: 31751608). The IL-6/JAK/STAT3 axis further promotes C3 expression.
**3. Aberrant Synaptic Pruning**
During development, C1Q normally tags weak synapses for microglial C3R-mediated pruning (PMID: 29900271). In AD, excessive C1Q/C3 deposition on synapses—particularly at vulnerable neurons—leads to accelerated complement-dependent phagocytosis, contributing to early synaptic loss before neuronal death.
**4. Neurotoxic Cascade**
C3a/C3b generation amplifies local inflammation and directly contributes to dendritic simplification and excitotoxicity.
## Testable Predictions
**1. Senescent cell burden correlates with complement expression:** In AD post-mortem tissue, quantification of p16^INK4a^-positive senescent cells should correlate with C1Q/C3 protein levels in regions showing synaptic loss (entorhinal cortex, hippocampus).
**2. SASP paracrine signaling drives complement in healthy glia:** Treatment of primary mouse microglia with conditioned media from senescent astrocytes should increase C1qa and C3 mRNA via NF-κB—confirmable with p65 nuclear translocation assays and abolished by IκB kinase inhibition.
**3. Senolytic intervention reduces complement and synaptic markers:** Pharmacological elimination of senescent cells (e.g., dasatinib/quercetin) in 5xFAD or 3xTg AD mice should decrease hippocampal C1Q/C3 deposition and preserve PSD95+ puncta density, supporting the causal direction.
This framework suggests **senolytics or complement inhibitors** as potential therapeutic approaches targeting upstream senescence rather than downstream complement alone.